Histology

Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies

Retrieved on: 
Wednesday, October 25, 2023
Science, Stem Cells, Biotechnology, Research, Optical, Health, Artificial Intelligence, Technology, RNA-Seq, Intelligence, AAV, B cell, Capsid, Cell, Geographic atrophy, Retinitis pigmentosa, IVT, Gene, Machine learning, Histology, ESGCT, Macaque, AAV2, Eye, European Society of Gene and Cell Therapy, Trigeminal ganglion, Patient, Retina, NHP, Crab-eating macaque, Vaccine, Dyno

The Dyno eCap 1 vector provides significantly improved delivery to the eye compared to other externally engineered capsids, including transduction throughout multiple layers of the retina.

Key Points: 
  • The Dyno eCap 1 vector provides significantly improved delivery to the eye compared to other externally engineered capsids, including transduction throughout multiple layers of the retina.
  • The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid.
  • The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile.
  • The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells.

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 24, 2023
NSCLC, American Society of Clinical Oncology, III, Biomarker, Water Quality Initiative, UPMC Hillman Cancer Center, Health, Research, AM, Society, Multimedia, Integra, Quality of life, PALM, Medicine, Histology, Abstract, HRR, Immunotherapy, Oncology, Lung cancer, Cancer, Patient, UPMC, ASCO, Nursing, Pharmaceutical industry, Stonemasonry, Medical imaging, MD

WEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023. The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes. Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.

Key Points: 
  • , the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.
  • Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.
  • The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care.
  • Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.

Versant Diagnostics Partners with Dahl-Chase Pathology and Diagnostic Groups

Retrieved on: 
Monday, October 23, 2023
Health, Practice Management, Other Health, General Health, Research, Science, Versant, Digital Pathology Association, Marie Cassidy, Pathology, Hospital Insurance and Diagnostic Services Act, Growth, Partnership, Histology, Hospital, Flow cytometry, Immunohistochemistry, Medical imaging

Versant Diagnostics , an independent physician services company focused on anatomic pathology, today announced its collaboration with Bangor, Maine-based Dahl-Chase Pathology Associates and Dahl-Chase Diagnostic Services .

Key Points: 
  • Versant Diagnostics , an independent physician services company focused on anatomic pathology, today announced its collaboration with Bangor, Maine-based Dahl-Chase Pathology Associates and Dahl-Chase Diagnostic Services .
  • Dahl-Chase serves hospitals and physician offices with surgical pathology, histology, immunohistochemistry, cytology, flow cytometry, and molecular diagnostics services.
  • “We believe Dahl-Chase has built a strong legacy as a trusted diagnostics and pathology resource for more than 50 years,” says Jim Billington, Chief Executive Officer at Versant Diagnostics.
  • This partnership is a perfect fit for Versant.”
    With more affiliations being developed for 2023 and 2024, Versant Diagnostics continues its growth strategy with groups like Dahl-Chase.

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

Retrieved on: 
Monday, October 23, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, DXD, Neoplasm, EGFR, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Lung cancer, Congress, PFS, MD, Docetaxel, European Society for Medical Oncology, CRS, HIV disease progression rates, R, Nausea, ADC, Daiichi Sankyo, Risk, Histology, ORR, ILD, Anemia, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, DXD, EGFR, Arm, PD-L1, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, Docetaxel, CRS, Doctor of Philosophy, HIV disease progression rates, R, Nausea, Lung, ADC, Daiichi Sankyo, Dor, TSE, Risk, Histology, ORR, ILD, Anemia, Platinum, Lung cancer, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% in patients treated with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan compared to 3.7 months in those treated with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

Personalized Medicine Key to IVD Procedure Volumes' 10% Annual Growth

Retrieved on: 
Monday, October 23, 2023
Pregnancy, Patient, Insurance, Pharmacology, Sale, Ageing, Incidence, Steam, IVD, Health, Physician, Molina Healthcare, Genetics, HIV, Histology, PCR, Abbott Laboratories, Microbiology, Growth, Disease, NGS, Fungal infection, COVID-19, Medicine, Hospital, Chemistry, Polymerase chain reaction, Eye, HAI, Diagnosis, Medical device, Vaccine, Medical imaging, Pharmaceutical industry, Immunoassay, Hematology, WHO model list of essential in vitro diagnostics

ARLINGTON, Va., Oct. 23, 2023 /PRNewswire/ -- The in vitro diagnostic (IVD) industry is on track again after the disruptions of the pandemic. The overall volume of IVD procedures will rise steadily throughout most of the world, boosted by aging population trends, proliferating epidemiological patterns, increasing availability of healthcare funding, and widespread adoption of patient care strategies that emphasize early disease detection and preventive medicine. As a result of these key factors, the global volume of IVD procedures is forecast to increase almost 10% annually from 2023-2028, according to the diagnostic market research report In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028.

Key Points: 
  • Beyond this, one of the most intriguing trends to watch is personalized medicine, which is also known as precision medicine.
  • IVD is an integral part of personalized medicine as it provides critical information needed to make treatment decisions.
  • Specific examples where IVD devices provide personalized medicine include blood glucose tests, pregnancy tests, cancer screening and in-home HIV testing.
  • Many of the IVD tests are benefiting from the uptake of personalized medicine which is expected to continue to increase.

Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress

Retrieved on: 
Friday, October 20, 2023
Research, Exact sciences, Multi, ESMO, Health, Biomarker, RNA, HER2, Congress, MD, Doctor of Philosophy, Paradigm, CEST, Development, ASCEND, NGS, Clinical trial, Risk, European Society for Medical Oncology, Cancer, Histology, Breast cancer, Oncology, Public, Woman, European Society of Gynaecological Oncology, FACP, Patient, Diagnosis, Exome, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Perfume

Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.

Key Points: 
  • Exact Sciences is taking a robust and rigorous approach to developing an MCED test, and today unveiled its brand name, Cancerguard.
  • Building upon decades of research, Exact Sciences is designing the Cancerguard test to harness the additive sensitivity of multiple biomarker classes to detect more early-stage cancers.
  • To learn more, visit http://www.exactsciences.com/cancerguard
    The company will host a symposium at the congress titled "Shifting the Paradigm of Cancer Detection: Multi Cancer Early Detection," featuring experts from leading oncology research institutions and Exact Sciences.
  • The European Society for Medical Oncology (ESMO) does not endorse any company, or their products/services.

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Retrieved on: 
Sunday, October 15, 2023
Congress, Histology, Senior, Fast track (FDA), NSCLC, Regeneron Pharmaceuticals, Genetics, Lung cancer, Survival, Translation, Carcinoma, Oncology, ESMO, Ovarian cancer, Melanoma, Immune system, CSCC, European Society for Medical Oncology, MUC16, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Cemiplimab

TARRYTOWN, N.Y., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the latest clinical data in early- and late-stage cancers from its oncology pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 to 24 in Madrid, Spain. The presentations demonstrate the role of Libtayo® (cemiplimab) as both a monotherapy and a backbone of novel investigational combinations for various solid tumors.

Key Points: 
  • The presentations demonstrate the role of Libtayo® (cemiplimab) as both a monotherapy and a backbone of novel investigational combinations for various solid tumors.
  • Beyond ESMO, we are excited by recent progress across our oncology portfolio, including FDA Fast Track Designation for fianlimab (LAG-3) plus Libtayo in melanoma.
  • Regeneron will also debut Phase 1 dose-escalation results for its investigational combination of Libtayo and ubamatamab in patients with heavily pretreated recurrent ovarian cancer in a poster session.
  • Ubamatamab is a CD3-targeting bispecific designed to bridge MUC16 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation.

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Retrieved on: 
Friday, October 13, 2023
Neoplasm, Pharmacokinetics, KRAS, Perforation, Plasma, Histology, BID, AACR, Standard of care, Aes, DNA, Risk, PDAC, Revolution, Safety, RAS, CRC, Diarrhea, Cancer, VAF, Oncology, OFF, Ovarian cancer, Rash, DCR, Stomatitis, Trae tha Truth, Patient, QT interval, Circulating tumor DNA, Hepatotoxicity, European Society for Medical Oncology, PR, Conference, Șaeș, Toxic leukoencephalopathy, Pharmaceutical industry, NSCLC, Eastern Time Zone

REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies. These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) in Boston, October 11-15, 2023.

Key Points: 
  • These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) in Boston, October 11-15, 2023.
  • “We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly.
  • Revolution Medicines will host an investor webcast on Sunday, October 22, 2023 at 12:30 p.m. Eastern Time to discuss the data presented at both the Triple Meeting and the 2023 European Society for Medical Oncology Congress, in addition to other clinical updates.
  • A live webcast of the call will also be available on the Investors section of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Retrieved on: 
Monday, October 9, 2023
Histology, Diabetes, DSM-IV codes, Safety, Fatty liver disease, NASH, Therapy, Event, Webcast, Cirrhosis, SAN, Fibrosis, EFX, Patient, Pharmaceutical industry, Online shopping, Åkerö

ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).

Key Points: 
  • ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).
  • The topline results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.
  • The company will host a conference call and webcast with slide presentation at 8:00 a.m.
  • The live webcast will be available on the Events & Presentations page of the Akero website, with the recording and presentation available immediately following the event.